Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Intellectual Disability01:29

Intellectual Disability

Intellectual disability (ID) is a neurodevelopmental condition characterized by deficits in intellectual and adaptive functioning that manifest during the developmental period. This condition encompasses challenges in reasoning, memory, problem-solving, and learning, accompanied by impairments in everyday life skills, such as communication, self-care, and social interactions. Intellectual disability affects approximately 1% of the population in the United States, impacting an estimated 5...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk and protective factors for cognitive decline in older adults from a nationally representative sample in India: Results from the LASI-DAD.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Loneliness and Plasma Biomarkers of Neurodegeneration in Community-Dwelling Older Adults: Cross-Sectional and Longitudinal Analyses.

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry·2026
Same author

Diabetes, impaired fasting glucose, and cognitive trajectories: a multi-cohort study.

medRxiv : the preprint server for health sciences·2026
Same author

CNS-selective plasma p-tau217 accurately captures Alzheimer's disease pathology and progression.

medRxiv : the preprint server for health sciences·2026
Same author

Olfaction, Cognition, and Early Signs of Neurodegenerative Disease in a Community-Based Sample of Older Adults.

Alzheimer disease and associated disorders·2026
Same author

CMV titer associations with cognition and the plasma proteome implicate FLT1 and neurovascular mechanisms as potential moderators.

Journal of neuroinflammation·2026

Related Experiment Video

Updated: Jun 4, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

Should mild cognitive impairment be subtyped?

Tiffany F Hughes1, Beth E Snitz, Mary Ganguli

  • 1Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Current Opinion in Psychiatry
|February 25, 2011
PubMed
Summary
This summary is machine-generated.

Subtyping mild cognitive impairment (MCI) aids in understanding its progression. Combining cognitive and biomarker approaches improves diagnostic accuracy for predicting dementia risk.

More Related Videos

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

Related Experiment Videos

Last Updated: Jun 4, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

Area of Science:

  • Neurology
  • Geriatrics
  • Cognitive Science

Background:

  • Mild cognitive impairment (MCI) is a heterogeneous condition.
  • Current diagnostic criteria do not fully capture etiological or prognostic differences.
  • Accurate subtyping is crucial for predicting dementia risk and guiding treatment.

Purpose of the Study:

  • To review the evidence on the validity and utility of recent methods for subtyping late-life MCI.
  • To assess the clinical utility of cognitive and biomarker-based MCI subtypes.
  • To identify areas for improvement in MCI classification.

Main Methods:

  • Literature review of studies on MCI subtyping.
  • Analysis of evidence regarding the validity and predictive value of cognitive subtypes.
  • Evaluation of approaches incorporating biomarkers for MCI classification.

Main Results:

  • Amnestic MCI is linked to Alzheimer's disease biomarkers and has a higher dementia progression risk.
  • Nonamnestic MCI is associated with cerebrovascular disease.
  • Multi-domain MCI indicates a more advanced disease state than single-domain MCI.
  • Biomarker-inclusive subtyping enhances diagnostic specificity and predictive value but requires further validation.

Conclusions:

  • MCI remains etiologically and prognostically heterogeneous, especially in non-specialty settings.
  • Further subtyping aims to create more clinically homogeneous subgroups.
  • Current cognitive subtypes offer some validity, but integrating biomarkers and exploring novel approaches is necessary to enhance their utility.